The annual meeting of the American Society for Clinical Oncology (ASCO) usually presents the findings of studies of great importance for the future treatment of head and neck cancer patients.
This year the results of a study carried out by the Institute of Cancer Research and the Royal Marsden suggested that immunotherapy was an effective first line treatment. In the UK immunotherapy has usually so far been a treatment of last resort when other treatments had failed. In the study the use of pembrolizumab was examined.
The study revealed clear benefits regarding survival outcomes from the use of immunotherapy as well as fewer side-effects.
Further information is available here